Open AccessMesenchymal stem cell-derived extracellular vesicles for cell-free therapy of ocular diseases
Author(s) -
Xiaoling Liu,
Liang Hu,
Fei Liu
Publication year - 2022
Publication title -
extracellular vesicles and circulating nucleic acids
Language(s) - English
Resource type - Journals
ISSN - 2767-6641
DOI - 10.20517/evcna.2022.08
Subject(s) - mesenchymal stem cell , paracrine signalling , cell therapy , medicine , extracellular vesicles , reprogramming , stem cell therapy , clinical trial , extracellular vesicle , cell , stem cell , microvesicles , cancer research , bioinformatics , pathology , biology , microbiology and biotechnology , microrna , biochemistry , gene , genetics , receptor
Mesenchymal stem cells-derived extracellular vesicles (MSC-EVs) have noticeably attracted clinicians’ attention in treating ocular diseases. As the paracrine factor of MSCs and an alternative for cell-free therapies, MSC-EVs can be conveniently dropped over the ocular surface or diffused through the retina upon intravitreal injection, without increasing the risks of cellular rejection and tumor formation. For clinical translation, a standardized and scalable production, as well as reprogramming the MSC-EVs, are highly encouraged. This review aims to assess the potential approaches for EV production and functional modification, in addition to summarizing the worldwide clinical trials initiated for various physiological systems and the specific biochemical effects of MSC-EVs on the therapy of eye diseases. Recent advances in the therapy of ocular diseases based on MSC-EVs are reviewed, and the associated challenges and prospects are discussed as well.